New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 14, 2012
07:44 EDTINCY, LLYIncyte weakness creates buying opportunity, says Oppenheimer
After Incyte (INCY) and partner Eli Lilly (LLY) reported Phase IIb results for their baricitinib in rheumatoid arthritis, Oppenheimer expects the drug to be approved in 2015-2016. The firm thinks the baricitinib program is doing well, and it maintains a $23 price target and Outperform rating on Incyte.
News For INCY;LLY From The Last 14 Days
Check below for free stories on INCY;LLY the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
July 31, 2014
13:39 EDTINCYIncyte reported strong Q2 results, says Leerink
Subscribe for More Information
13:18 EDTINCYIncyte shares defended at UBS
Subscribe for More Information
12:52 EDTINCYIncyte weakness a buying opportunity, says Brean Capital
Subscribe for More Information
10:02 EDTLLYOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
07:22 EDTINCYIncyte raises FY14 Jakafi net product revenue view to $330M-$340M
Subscribe for More Information
07:15 EDTINCYIncyte reports Q2 EPS (22c), may not compare to consensus (4c)
Reports Q2 revenue $99.6M, consensus $127.19M.
06:10 EDTLLYEli Lilly downgraded to Neutral from Buy at Citigroup
Citigroup downgraded Eli Lilly (LLY) to Neutral saying Alimta upside and the company's pipeline is largely priced into shares at current levels. Citi raised its price target for Lilly shares to $66 from $60 and said it prefers Bristol-Myers (BMY) and Pfizer (PFE) in the U.S.
July 30, 2014
08:32 EDTINCYIncyte announces clinical trial agreement with Genentech
Subscribe for More Information
July 29, 2014
08:50 EDTLLYHarris & Harris invests in Accelerator Corporation
Subscribe for More Information
July 28, 2014
07:02 EDTINCYIncyte says FDA approves supplemental labeling for Jakafi
Subscribe for More Information
July 24, 2014
09:26 EDTLLYEli Lilly CEO says company on track to meet FY goals
Subscribe for More Information
06:57 EDTINCYIncyte trial miss does not impact Jakafi assumptions, says Leerink
Subscribe for More Information
06:38 EDTLLYEli Lilly says Q2 revenue declined 17% due to patent expirations
Subscribe for More Information
06:37 EDTLLYEli Lilly sees research, development charge of $45M in Q3
In July, Eli Lilly announced a co-discovery and co-development collaboration with Immunocore to research and potentially develop novel T cell-based cancer therapies. As a result of the transaction, the company expects to incur an in-process research and development charge of $45M, or approximately 3c per share Q3. In Q2, the company recognized asset impairment, restructuring and other special charges of $63.5M, primarily related to costs associated with the decision to close a packaging and distribution facility in Germany.
06:35 EDTLLYEli Lilly reaffirms 2014 EPS outlook $2.72-$2.80, consensus $2.78
Subscribe for More Information
06:33 EDTLLYEli Lilly reports Q2 EPS 68c, consensus 65c
Reports Q2 revenue $4.94B, consensus $4.9B.
July 23, 2014
16:41 EDTINCYIncyte's Ruxolitinib shows no statistical significance in primary endpoint
Subscribe for More Information
15:30 EDTLLYNotable companies reporting before tomorrow's open
Notable companies reporting before tomorrow's market open, with earnings consensus, include Ford (F), consensus 36c; General Motors (GM), consensus 58c; Potash (POT), consensus 46c; Caterpillar (CAT), consensus $1.52; 3M (MMM), consensus $1.91; Union Pacific (UNP), consensus $1.43; Bristol-Myers Squibb (BMY), consensus 44c; Eli Lilly (LLY), consensus 65c; Celgene (CELG), consensus 89c; Precision Castparts (PCP), consensus $3.35; Raytheon (RTN), consensus $1.59; Noble Energy (NBL), consensus 79c; Hershey (HSY), consensus 76c; Southwest Airlines (LUV), consensus 61c; Boston Scientific (BSX), consensus 19c; JetBlue (JBLU), consensus 19c.
14:06 EDTLLYEarnings Preview: Lilly counts on newer drugs to drive revenue
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use